Product Information
Registration Status: ActiveSIN14395P
FLUOROURACIL INJECTION 50MG/ML is approved to be sold in Singapore with effective from 2013-08-20. It is marketed by MYLAN PHARMACEUTICALS PTE LTD, with the registration number of SIN14395P.
This product contains Fluorouracil 50mg/ml in the form of INJECTION, SOLUTION. It is approved for INTRAVENOUS, INTRA-ARTERIAL use.
This product is manufactured by Onco Therapies LTD in INDIA.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. [PubChem]
Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
Mechanism of Action
The precise mechanism of action has not been fully determined, but the main mechanism of fluorouracil is thought to be the binding of the deoxyribonucleotide of the drug (FdUMP) and the folate cofactor, N5–10-methylenetetrahydrofolate, to thymidylate synthase (TS) to form a covalently bound ternary complex. This results in the inhibition of the formation of thymidylate from uracil, which leads to the inhibition of DNA and RNA synthesis and cell death. Fluorouracil can also be incorporated into RNA in place of uridine triphosphate (UTP), producing a fraudulent RNA and interfering with RNA processing and protein synthesis.
Pharmacokinetics
- Absorption
- 28-100%
- Distribution
- Metabolism
- Hepatic. The catabolic metabolism of fluorouracil results in degradation products ( e.g., CO2, urea and α-fluoro-ß-alanine) which are inactive.
- Elimination
Toxicity
LD50=230mg/kg (orally in mice)
Active Ingredient/Synonyms
5-Fluoracil | 5-Fluoropyrimidine-2,4-dione | 5-Fluorouracil | 5-Fluracil | 5-FU | Fluoro Uracil | Fluorouracil | Fluorouracilo | Fluorouracilum | Fluoruracil | Fluouracil | FU | Fluorouracil |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.